Distribution and determinants of coronary artery calcium score in asymptomatic patients with Type-2 diabetes: The French-CAC100 score.

Cardiovascular Coronary artery calcium score Diabetes Primary prevention Risk factors

Journal

Diabetes research and clinical practice
ISSN: 1872-8227
Titre abrégé: Diabetes Res Clin Pract
Pays: Ireland
ID NLM: 8508335

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 23 03 2023
revised: 25 07 2023
accepted: 10 08 2023
pubmed: 13 8 2023
medline: 13 8 2023
entrez: 12 8 2023
Statut: ppublish

Résumé

Coronary artery calcium score (CACS) refines the cardiovascular disease (CVD) risk prediction in patients with Type-2 diabetes (T2D). We aimed to identify the determinants for high CACS in CVD-free patients with T2D. We studied 796 patients with T2D with CACS measured in three centers: two in continental France and a third in the Reunion Island. To predict a CACS ≥ 100, we derived a risk score in patients in continental France, and validated it in those in the Reunion Island. The distributions of CACS distributions were similar among patients in continental France and Reunion Island. The French-CAC100 score included 5 parameters (age, sex, diabetes duration, non-CV end-organ damage and presence of ≥ 2 other CVD risk factors), ranging from 0 to 22 points. Similar areas under the curves were found for the risk score in both settings (0.80 vs. 0.73, p = 0.10). A French-CAC100 score < 10 excluded the odds for CACS ≥ 100 and CACS ≥ 400 with negative predictive values of 90% and 97% respectively, avoiding 58% of CT-scans. Regardless of the geographic area, patients with T2D share similar risk factors for high CACS. The French-CAC100 score allows the identification of those at higher risk of elevated CACS.

Sections du résumé

BACKGROUND BACKGROUND
Coronary artery calcium score (CACS) refines the cardiovascular disease (CVD) risk prediction in patients with Type-2 diabetes (T2D). We aimed to identify the determinants for high CACS in CVD-free patients with T2D.
METHODS METHODS
We studied 796 patients with T2D with CACS measured in three centers: two in continental France and a third in the Reunion Island. To predict a CACS ≥ 100, we derived a risk score in patients in continental France, and validated it in those in the Reunion Island.
RESULTS RESULTS
The distributions of CACS distributions were similar among patients in continental France and Reunion Island. The French-CAC100 score included 5 parameters (age, sex, diabetes duration, non-CV end-organ damage and presence of ≥ 2 other CVD risk factors), ranging from 0 to 22 points. Similar areas under the curves were found for the risk score in both settings (0.80 vs. 0.73, p = 0.10). A French-CAC100 score < 10 excluded the odds for CACS ≥ 100 and CACS ≥ 400 with negative predictive values of 90% and 97% respectively, avoiding 58% of CT-scans.
CONCLUSION CONCLUSIONS
Regardless of the geographic area, patients with T2D share similar risk factors for high CACS. The French-CAC100 score allows the identification of those at higher risk of elevated CACS.

Identifiants

pubmed: 37572948
pii: S0168-8227(23)00634-4
doi: 10.1016/j.diabres.2023.110871
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110871

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Mamadou Adama Sow (MA)

EpiMaCT -INSERM 1094 & IRD290, University of Limoges, 87025, 2, Rue Marcland, Limoges, France; Department of Cardiology, Dupuytren 2 University Hospital, 16, Rue B. Descottes, 87042, Limoges, France. Electronic address: mamadouadama403@gmail.com.

Guillaume Treiber (G)

Inserm U1188 Diabète Athérothrombose Thérapies Réunion Océan Indien, France.

Emmanuel Cosson (E)

Department of Endocrinology-Diabetology-Nutrition, Avicenne Hospital, AP-HP, Bobigny, France.

Yves Mutunzi (Y)

EpiMaCT -INSERM 1094 & IRD290, University of Limoges, 87025, 2, Rue Marcland, Limoges, France; Department of Cardiology, Dupuytren 2 University Hospital, 16, Rue B. Descottes, 87042, Limoges, France.

Julien Magne (J)

EpiMaCT -INSERM 1094 & IRD290, University of Limoges, 87025, 2, Rue Marcland, Limoges, France; Department of Cardiology, Dupuytren 2 University Hospital, 16, Rue B. Descottes, 87042, Limoges, France.

Cyrille Boulogne (C)

Department of Cardiology, Dupuytren 2 University Hospital, 16, Rue B. Descottes, 87042, Limoges, France.

Laurence Salle (L)

EpiMaCT -INSERM 1094 & IRD290, University of Limoges, 87025, 2, Rue Marcland, Limoges, France; Department of Endocrinology, Diabetology and Metabolism, Dupuytren 2 University Hospital, 16, Rue B. Descottes, 87042, Limoges, France.

Marouane Boukhris (M)

Department of Cardiology, Dupuytren 2 University Hospital, 16, Rue B. Descottes, 87042, Limoges, France.

Estelle Nobecourt (E)

Inserm U1188 Diabète Athérothrombose Thérapies Réunion Océan Indien, France; Inserm U1410, Reunion University Hospital, Reunion Island, France.

Victor Aboyans (V)

EpiMaCT -INSERM 1094 & IRD290, University of Limoges, 87025, 2, Rue Marcland, Limoges, France; Department of Cardiology, Dupuytren 2 University Hospital, 16, Rue B. Descottes, 87042, Limoges, France. Electronic address: victor.aboyans@chu-limoges.fr.

Classifications MeSH